ANZCTR search results

Over 80% of people living with spinal cord injury (SCI) have sleep apnoea. This study will investigate the feasibility of a novel physiotherapy-led outpatient model for identifying and managing sleep apnoea in SCI. People attending outpatient clinics of two state-wide SCI services (Victoria and Queensland) will be screened for risk of sleep apnoea. Those at risk will be referred to a highly trained neuro-respiratory physiotherapist, located within the health service and supported by a respiratory specialist, for ambulatory investigations and management. A thorough process evaluation will assess the feasibility of this alternative care model and estimate the impact on important clinical outcomes.

This is a triple-blind, randomised, placebo-controlled trial investigating whether a single intravesical dose of tranexamic acid (TXA) reduces the duration of continuous bladder irrigation (CBI) in adults presenting to the Emergency Department with macroscopic haematuria. Macroscopic haematuria (blood visible in urine) can cause clots in the bladder, leading to urinary obstruction that requires a bladder catheter and CBI. TXA is a medicine that helps stop bleeding by preventing clot breakdown. Adults aged 18 or over with macroscopic haematuria requiring CBI will be randomly assigned to receive either 1000mg TXA in 100ml saline or a placebo (100ml saline alone), instilled into the bladder via urinary catheter and clamped for 15 minutes before CBI starts. Neither participants nor treating staff will know which treatment is given. The main outcome is how long CBI is needed. Secondary outcomes include hospital admission rates, emergency department re-presentations, catheter duration, and safety outcomes including venous thromboembolism. 80 participants will be recruited across four Emergency Departments in the Illawarra Shoalhaven Local Health District, NSW, over 12 months.

This randomised controlled feasibility trial will evaluate domiciliary Humidified High Flow Therapy (HHFT) in patients with COPD/Bronchiectasis. The primary aim is to determine the feasibility of a larger adequately powered trial and explore potential effects on exacerbation frequency, patient comfort, quality of life, and hospital admissions. Sixty participants will be recruited from respiratory inpatients/outpatients across two sites and randomised (1:1) to HHFT plus standard care or standard care alone. Intervention participants will use HHFT overnight where possible, or for a minimum of four hours per twenty-four hour period. Participants, once recruited will be discharged home or transferred to Hospital in the Home (HiTH) and will be followed at weeks 1-3 by telephone, week 4 face-to-face and month 2and 3 (study completion) by telephone. Adverse events and device performance will be monitored throughout the study period.

evaluating the safety, tolerability, and proof-of-concept efficacy of the investigational production BromAc® administered intra-articular in addition to standard-of-care suppressive antibiotic therapy. Participants will be followed for 90 days with clinical, laboratory, and patient-reported outcome assessments. It is hypothesized that BromAc will be safe and tolerable, with potential improvement in symptoms

This study explores how advanced hearing aids using artificial intelligence (AI) can help individuals with auditory neuropathy to better understand speech in noisy environments. The research will compare these advanced devices to traditional hearing aids by testing how well individuals hear and identify the location of sounds in a laboratory setting and during a eight-week trial. The goal is to determine whether AI-hearing aids provide better speech clarity and listening comfort in complex situations. The findings will help improve recommendations for individuals with auditory neuropathy and determine whether advanced hearing technology is more capable at enhancing communication than traditional technology. Individuals participating in the study will contribute valuable insights into the daily challenges of listening in noisy environments.

This research seeks to explore whether it is possible to modify treatment credibility and expectancy in patients undertaking a low FODMAP diet and assess if potential increases in treatment expectancy impact the diet's efficacy. It is expected that the use of optimistic realism and positive expectations as part of the dietary counselling will enhance dietary adherence, symptom response, quality-of-life response, and treatment satisfaction.

Brief description of the study purpose This study aims to evaluate the feasibility of giving platelet (a blood product) transfusions in a patient’s home and the costs, safety and acceptability of the program. Who is it for? You may be eligible for this study if you are male or female, aged 18 or older, diagnosed with haematological malignancy (most commonly Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Lymphoma or Myeloma) and requiring platelet transfusions during your treatment. Study details Platelet (blood product) transfusion will be given by nursing staff to select patients with haematological malignancy (blood cancer) in the patient’s own home, instead of in the hospital. This will occur up to 3 times per week for up to 12 weeks. It is hoped that the results from this study will help improves patient comfort, reduces caregiver burden, reduces the use of inpatient hospital beds, and may reduce costs for those requiring blood transfusion.

We know from the Australian Institute of Health and Welfare 2021, that almost 1 in 2 (46.5%) of women giving birth for the first time (nulliparous), will require artificial commencement of their labour - known as induction of labour. Of these nulliparous women having an induction of labour, a majority of them (73%) will require an operative birth (forceps, vacuum or emergency caesarean section). We believe that the existing management of induction of labour is contributing to the incidence of operative births and furthermore, it is also resulting in excessively long labours. Our hypothesis is that the use of an intermittent infusion (pulsatile) of oxytocin will reduce the duration of labour when compared to the current use of a continuous infusion of oxytocin. We will test our hypothesis by a randomised controlled trial of 220 nulliparous women who require an induction of labour by randomising them to either a continuous infusion or intermittent infusion of oxytocin, in a blinded fashion.

The Health4Life Parents & Teens study aims to test a new digital intervention to improve six key health risk behaviours in adolescents: physical inactivity, poor nutrition, alcohol use, smoking/vaping, screen time, and poor sleep. This study will test the effects of the combined student-and-parent program in improving teenage health habits, especially those facing disadvantage. The Health4Life student program, which will be delivered to Year 7 students during PHDPE class, uses interactive cartoons to encourage young people to adopt the six key health behaviours. This program has been adapted to specifically help young people experiencing socioeconomic disadvantage. The Health4Life parent program compliments this, providing parents with online modules and tailored feedback about their parenting practices in relation to the six key health behaviours. Findings will provide evidence about the efficacy of this digital program in reducing key health risk behaviours among teenagers experiencing disadvantage, and much-needed cost-effectiveness data.

The purpose of the study is to identify if brain waves recorded during anaesthesia and surgery can be used to predict if patients will develop delirium after surgery. We will collect brain wave activity from patients using a special cap (similar to a shower cap). We will also collect blood from patients to measure proteins that might also indicate their risk of developing delirium. The aim is to predict patients who might develop delirium in order to help prevent this complication of anaesthesia and surgery.